Evidence map›Paper›PMID 20966765›Full record

ArticleJournal of cardiovascular pharmacology2011

Mitochondria-targeted cardioprotection in aldosteronism.

Atta U Shahbaz, German Kamalov, Wenyuan Zhao, Tieqiang Zhao, Patti L Johnson, Yao Sun, Syamal K Bhattacharya, Robert A Ahokas, Ivan C Gerling, Karl T Weber

Abstract readComparative Study
In one paragraph

Article in Journal of cardiovascular pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Quercetin treatment increases HNaunyn-Schmiedeberg's archives of pharmacology · 2021
    Article
  5. Potential Implications of Quercetin and its Derivatives in Cardioprotection.International journal of molecular sciences · 2020
    Review
  6. Article
  7. Myofibroblast secretome and its auto-/paracrine signaling.Expert review of cardiovascular therapy · 2016
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Atrophic cardiomyocyte signaling in hypertensive heart disease.Journal of cardiovascular pharmacology · 2013
    Article
  13. Review
  14. Reverse remodeling and recovery from cachexia in rats with aldosteronism.American journal of physiology. Heart and circulatory physiology · 2012
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Atta U ShahbazDivision of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
German Kamalov
Wenyuan Zhao
Tieqiang Zhao
Patti L Johnson
Yao Sun
Syamal K Bhattacharya
Robert A Ahokas
Ivan C Gerling
Karl T Weber
National Institute of Cardiovascular Diseases · BDUniversity of Tennessee Health Science Center · USDiabetes Australia · AU

Funding

Aldosteronism: An Immunostimulatory StateR01HL073043 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI WEBER, KARL T · 2004 to 2008
$1.8M
Recovery from Cachexia in Heart and Skeletal MuscleR01HL090867 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI WEBER, KARL T · 2008 to 2011
$1.5M
Regulatory Mechanisms of Oxidative Stress in Hypertensive Heart DiseaseR01HL096813 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI WEBER, KARL T · 2010 to 2013
$1.5M
NHLBI NIH HHS R01 HL073043NHLBI NIH HHS R01 HL090867NHLBI NIH HHS R01 HL096813NHLBI NIH HHS R01-HL73043NHLBI NIH HHS R01-HL90867
6 · The paper itself

Abstract

Chronic aldosterone/salt treatment (ALDOST) is accompanied by an adverse structural remodeling of myocardium that includes multiple foci of microscopic scarring representing morphologic footprints of cardiomyocyte necrosis. Our previous studies suggested that signal-transducer-effector pathway leading to necrotic cell death during ALDOST includes intramitochondrial Ca overloading, together with an induction of oxidative stress and opening of the mitochondrial permeability transition pore (mPTP). To further validate this concept, we hypothesized that mitochondria-targeted interventions will prove to be cardioprotective. Accordingly, 8-week-old male Sprague-Dawley rats receiving 4 weeks ALDOST were cotreated with either quercetin, a flavonoid with mitochondrial antioxidant properties, or cyclosporine A (CsA), an mPTP inhibitor, and compared with ALDOST alone or untreated, age/sex-matched controls. We monitored mitochondrial free Ca and biomarkers of oxidative stress, including 8-isoprostane and H2O2 production; mPTP opening; total Ca in cardiac tissue; and collagen volume fraction to quantify replacement fibrosis, a biomarker of cardiomyocyte necrosis, and employed terminal deoxynucleotidyl transferase dUTP nick end labeling assay to address apoptosis in coronal sections of ventricular myocardium. Compared with controls, at 4 weeks ALDOST we found a marked increase in mitochondrial H2O2 production and 8-isoprostane levels, an increased propensity for mPTP opening, and greater concentrations of mitochondrial free [Ca]m and total tissue Ca, coupled with a 5-fold rise in collagen volume fraction without any terminal deoxynucleotidyl transferase dUTP nick end labeling-based evidence of cardiomyocyte apoptosis. Each of these pathophysiologic responses to ALDOST was prevented by quercetin or cyclosporine A cotreatment. Thus, mitochondria play a central role in initiating the cellular-subcellular mechanisms that lead to necrotic cell death and myocardial scarring. This destructive cycle can be interrupted and myocardium salvaged with its structure preserved by mitochondria-targeted cardioprotective strategies.

Indexed as

AldosteroneAnimalsAntioxidantsCalciumCardiotonic AgentsCyclosporineDinoprostHydrogen PeroxideHyperaldosteronismMaleMitochondriaMitochondrial Membrane Transport ProteinsMyocardiumMyocytes, CardiacOxidative StressQuercetin8-epi-prostaglandin F2alphaAldosteroneAntioxidantsCalciumCardiotonic AgentsCyclosporineDinoprostHydrogen PeroxideMitochondrial Membrane Transport ProteinsQuercetin

Identifiers

PMID20966765
PMCPMC3022960
OpenAlexW2037029417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.